Ulocuplumab
| Ulocuplumab | |
|---|---|
| [[File:|frameless|220px|alt=|]] | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Ulocuplumab is an experimental monoclonal antibody designed for the treatment of various types of cancer. It targets the CXCR4 chemokine receptor, which is involved in tumor growth and metastasis. The development of ulocuplumab aims to inhibit the interaction between CXCR4 and its ligand, CXCL12, which is a critical pathway in cancer cell migration and proliferation.
Mechanism of Action[edit | edit source]
Ulocuplumab binds to the CXCR4 receptor on the surface of tumor cells. By blocking this receptor, ulocuplumab prevents CXCL12 from binding to CXCR4, thereby inhibiting cancer cell migration and survival. This blockade can potentially reduce tumor growth and prevent the spread of cancer cells to other parts of the body.
Clinical Trials[edit | edit source]
Clinical trials for ulocuplumab have been conducted to evaluate its efficacy and safety in treating various cancers, including multiple myeloma, leukemia, and solid tumors. These studies assess the antibody's ability to improve survival rates and reduce tumor burden in patients.
Potential Side Effects[edit | edit source]
As with any cancer therapy, ulocuplumab may cause side effects. The most common adverse effects observed in clinical trials include nausea, fatigue, and fever. More severe complications can occur, depending on the patient's overall health and other treatments they are receiving.
Future Prospects[edit | edit source]
Research is ongoing to determine the full potential of ulocuplumab in cancer therapy. If successful, it could become part of standard treatment regimens for certain cancers, particularly those that are highly sensitive to CXCR4/CXCL12 signaling.
See Also[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
